Non-Hodgkin Lymphoma Perspective

 
 
  • Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.
  • Negative Trials, CAR T Studies Lead ASH Lymphoma Highlights   Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials.
  • Don't Miss Thyroid Disease in Kids Thyroid disease in children is surprisingly common -- and frequently missed. Dr Andrew Bauer provides key strategies to be sure these kids do not fall through the cracks.
  • ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment Dr Miguel-Angel Perales summarizes key recent developments in the field of CAR T cells and outlines the most important CAR T cell trials to follow at the 2016 ASH Annual Meeting.
  • No Lack of Enthusiasm for CAR-T Development, Experts Say Medscape Oncology asked a spectrum of researchers in the field to speculate on the implications of Novartis's decision to reintegrate cell therapy into its oncology unit.
  • Comorbidities in Inflammatory Joint Disease   Drs Paget and Schwartzman discuss both rare and common comorbidities, and the latest strategies to prevent their damaging effects.
  • Quiz: Which Presidential Candidates Had Health Issues? This isn't the first presidential election in which candidates' health has been scrutinized; can you remember the earlier cases?
  • A New Oncology Target: The Heart Delivering the most effective dose of chemotherapy without causing cardiotoxicity is a key goal of the emerging field of cardio-oncology. But are the current predictors of cardiotoxic risk adequate?
  • Malpractice Risk: The Dangers of False Positives An erroneous diagnosis borne from a misinterpreted test result can subject patients to unnecessary procedures, emotional trauma, and medical regimens that can alter their lives.
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • European Hematology Association (EHA) 2016 Congress Read clinically focused news coverage of key developments from EHA 2016.
  • Reducing Inequality With Precision Public Health   Eric Topol talks with Sue Desmond-Hellmann about her multidimensional career and how to scale precision medicine for global public health.
  • What's Hot in Hematologic Malignancies   Dr Bruce Cheson gives a sneak preview of the presentations in hematologic malignancies at ASCO 2016, with a look at new agents, refined combinations, and strategies to reduce toxicities.
  • ASCO's TAPUR Study: Off-Label Drugs for Actionable Mutations Dr Edward Kim, a principal investigator in ASCO's TAPUR study, describes the trial's unique approach to evaluating the efficacy of targeted cancer therapies prescribed off-label.
  • High Value for Vascular Care? Perhaps Not for Some Dr Melissa Walton-Shirley sits in on a session on peripheral vascular care and finds out that too much is spent as well as not enough, that some are overtreated and others ignored.
  • Young Adult Cancer Survivors Hard Hit by Treatment Costs New studies indicate that young adult cancer survivors are more vulnerable than others to the financial toxicity of their treatment.
  • Idelalisib Speed Bump: Shifting Gears in CLL   Dr Bruce Cheson discusses how the halt of six idelalisib trials because of adverse events, including deaths, affects research and patient management in CLL and follicular lymphoma.
  • New Hodgkin's Protocol: Brentuximab Vedotin and Nivolumab   The new treatment protocol may advance the goal of phasing out the use of nonspecific, cytotoxic chemotherapy as a treatment for this disease.
  • Checkpoint Inhibitors in Hematologic Cancers: Overview Checkpoint inhibitors hold promise for the treatment of hematologic cancers, but they may require additional agents to reach their full potential.
  • Can Gonads Be Protected During Chemotherapy? Can the use of gonadotropin-releasing hormone analogue during chemotherapy protect the ovaries from gonadal toxicity and preserve fertility?
www.pharmacy24.com.ua

rezeptfrei-viagra.com/

Купить Камагра Polo